China's first large-scale real-world study of anti-COVID-19 drugs will include real data from 40, 000 COVID-19 patients. China's first large-scale real-world study on listed anti-novel coronavirus drugs was officially launched in Beijing. The study, which involves 30 provinces, municipalities and autonomous regions, more than 100 large hospitals and grass-roots health care institutions, will include the real data of nearly 40, 000 COVID-19 patients.